Atorvastatin
Atorvaliq, Caduet, Lipitor, Liptruzet (atorvastatin) is a small molecule pharmaceutical. Atorvastatin was first approved as Lipitor on 1996-12-17. It is used to treat coronary artery disease, hypercholesterolemia, hyperlipoproteinemias, and hypertriglyceridemia in the USA. The pharmaceutical is active against 3-hydroxy-3-methylglutaryl-Coenzyme A reductase.
Download report
Favorite
Top Prescription Drugs
Top 200 Pharmaceuticals by Retail Sales
Commercial
Trade Name
FDA
EMA
Atorvaliq, Lipitor (generic drugs available since 2011-11-30)
CombinationsCaduet (generic drugs available since 2011-11-30, discontinued: Liptruzet)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| atorvaliq | New Drug Application | 2023-02-16 |
| atorvastatin calcium | ANDA | 2023-06-16 |
| caduet | New Drug Application | 2021-03-25 |
| lipitor | New Drug Application | 2021-11-16 |
| lypqozet | ANDA | 2021-01-14 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| coronary artery disease | — | D003324 | I25.1 |
| hypercholesterolemia | HP_0003124 | D006937 | — |
| hyperlipoproteinemias | — | D006951 | — |
| hypertriglyceridemia | EFO_0004211 | D015228 | — |
Agency Specific
FDA
EMA
No data
ATC Codes
C: Cardiovascular system drugs
— C10: Lipid modifying agents
— C10A: Lipid modifying agents, plain
— C10AA: Hmg coa reductase inhibitors, plain lipid modifying drugs
— C10AA05: Atorvastatin
— C10B: Lipid modifying agents, combinations
— C10BA: Combinations of various lipid modifying agents
— C10BA05: Atorvastatin and ezetimibe
— C10BA08: Atorvastatin and omega-3 fatty acids
— C10BX: Lipid modifying agents in combination with other drugs
— C10BX03: Atorvastatin and amlodipine
— C10BX06: Atorvastatin, acetylsalicylic acid and ramipril
— C10BX08: Atorvastatin and acetylsalicylic acid
— C10BX11: Atorvastatin, amlodipine and perindopril
— C10BX12: Atorvastatin, acetylsalicylic acid and perindopril
— C10BX15: Atorvastatin and perindopril
— C10BX18: Atorvastatin, amlodipine and ramipril
HCPCS
No data
Clinical
Clinical Trials
825 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypercholesterolemia | D006937 | HP_0003124 | 7 | 17 | 59 | 39 | 8 | 130 | |
| Dyslipidemias | D050171 | HP_0003119 | 6 | 11 | 25 | 27 | 3 | 72 | |
| Hyperlipidemias | D006949 | EFO_0003774 | E78.5 | 10 | 10 | 27 | 8 | 2 | 55 |
| Healthy volunteers/patients | — | 44 | 1 | — | 6 | 3 | 54 | ||
| Coronary artery disease | D003324 | I25.1 | — | 2 | 10 | 23 | 10 | 45 | |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | 6 | 5 | 17 | 7 | 35 |
| Hypertension | D006973 | EFO_0000537 | I10 | 5 | 2 | 6 | 15 | 4 | 32 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 1 | — | 8 | 14 | 5 | 28 |
| Atherosclerosis | D050197 | EFO_0003914 | I25.1 | — | 1 | 7 | 14 | 6 | 28 |
| Coronary disease | D003327 | 1 | — | 8 | 11 | — | 20 |
Show 92 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 2 | 9 | 1 | — | — | 11 |
| Prostatic neoplasms | D011471 | C61 | 1 | 4 | 2 | — | 2 | 9 | |
| Covid-19 | D000086382 | U07.1 | — | 2 | 5 | — | 2 | 8 | |
| Hyperlipoproteinemia type ii | D006938 | EFO_0004911 | E78.00 | — | — | 6 | — | 1 | 7 |
| Chronic periodontitis | D055113 | EFO_0006343 | K05.3 | — | 6 | 5 | — | — | 6 |
| Hiv | D006678 | O98.7 | 1 | 2 | 1 | — | 1 | 5 | |
| Subdural hematoma chronic | D020200 | — | 2 | 1 | — | 1 | 4 | ||
| Myelodysplastic syndromes | D009190 | D46 | 1 | 2 | 1 | — | — | 4 | |
| Myeloid leukemia acute | D015470 | C92.0 | 1 | 2 | 1 | — | — | 4 | |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | C91.0 | — | 3 | 1 | — | — | 4 |
Show 36 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | 1 | 2 | — | — | 2 | 5 |
| Obstructive sleep apnea | D020181 | EFO_0003918 | G47.33 | 3 | 2 | — | — | — | 4 |
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | 2 | — | — | 1 | 3 |
| Cardiotoxicity | D066126 | EFO_1001482 | — | 3 | — | — | — | 3 | |
| Mucocutaneous lymph node syndrome | D009080 | EFO_0004246 | M30.3 | 2 | 2 | — | — | — | 3 |
| Balloon angioplasty coronary | D015906 | EFO_0003951 | — | 2 | — | — | 1 | 3 | |
| Triple negative breast neoplasms | D064726 | — | 2 | — | — | — | 2 | ||
| Relapsing-remitting multiple sclerosis | D020529 | EFO_0003929 | — | 2 | — | — | — | 2 | |
| Colorectal neoplasms | D015179 | — | 1 | — | — | 1 | 2 | ||
| Adenocarcinoma | D000230 | 1 | 1 | — | — | — | 2 |
Show 59 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | 1 | — | — | — | 1 | 2 |
| Pharmacokinetics | D010599 | 2 | — | — | — | — | 2 | ||
| Infections | D007239 | EFO_0000544 | 1 | — | — | — | 1 | 2 | |
| Hereditary nonpolyposis colorectal neoplasms | D003123 | EFO_0007354 | 1 | — | — | — | — | 1 | |
| Autonomic nervous system diseases | D001342 | EFO_0009532 | G90 | 1 | — | — | — | — | 1 |
| Lipodystrophy | D008060 | E88.1 | 1 | — | — | — | — | 1 | |
| Hiv seronegativity | D018023 | 1 | — | — | — | — | 1 | ||
| Epilepsy | D004827 | EFO_0000474 | G40.9 | 1 | — | — | — | — | 1 |
| Sleep wake disorders | D012893 | G47 | 1 | — | — | — | — | 1 | |
| Drug interactions | D004347 | 1 | — | — | — | — | 1 |
Show 5 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Percutaneous coronary intervention | D062645 | — | — | — | — | 2 | 2 | ||
| Asymptomatic diseases | D058070 | — | — | — | — | 2 | 2 | ||
| Diastolic heart failure | D054144 | EFO_1000899 | I50.30 | — | — | — | — | 2 | 2 |
| Coronary occlusion | D054059 | I21 | — | — | — | — | 1 | 1 | |
| Proteinuria | D011507 | HP_0000093 | R80 | — | — | — | — | 1 | 1 |
| Inborn genetic diseases | D030342 | EFO_0000508 | — | — | — | — | 1 | 1 | |
| Hypoalphalipoproteinemias | D052456 | E78.6 | — | — | — | — | 1 | 1 | |
| Delirium | D003693 | R41.0 | — | — | — | — | 1 | 1 | |
| Altitude sickness | D000532 | EFO_1000782 | T70.29 | — | — | — | — | 1 | 1 |
| Cancer pain | D000072716 | G89.3 | — | — | — | — | 1 | 1 |
Show 10 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | ATORVASTATIN |
| INN | atorvastatin |
| Description | Atorvastatin is a dihydroxy monocarboxylic acid that is a member of the drug class known as statins, used primarily for lowering blood cholesterol and for preventing cardiovascular diseases. It has a role as an environmental contaminant and a xenobiotic. It is an aromatic amide, a member of monofluorobenzenes, a statin (synthetic), a dihydroxy monocarboxylic acid and a member of pyrroles. It is functionally related to a heptanoic acid. It is a conjugate acid of an atorvastatin(1-). |
| Classification | Small molecule |
| Drug class | enzyme inhibitors: antihyperlipidemics (HMG-CoA inhibitors) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O |
Identifiers
| PDB | 1HWK |
| CAS-ID | 134523-00-5 |
| RxCUI | 83367 |
| ChEMBL ID | CHEMBL1487 |
| ChEBI ID | 39548 |
| PubChem CID | 60823 |
| DrugBank | DB01076 |
| UNII ID | A0JWA85V8F (ChemIDplus, GSRS) |
Target
Agency Approved
HMGCR
HMGCR
Organism
Homo sapiens
Gene name
HMGCR
Gene synonyms
NCBI Gene ID
Protein name
3-hydroxy-3-methylglutaryl-Coenzyme A reductase
Protein synonyms
3-hydroxy-3-methylglutaryl CoA reductase (NADPH), HMG-CoA reductase, hydroxymethylglutaryl-CoA reductase
Uniprot ID
Mouse ortholog
Hmgcr (15357)
3-hydroxy-3-methylglutaryl-coenzyme A reductase (Q5U4I2)
Alternate
No data
Variants
Clinical Variant
Identifier | Target mutation | Effect | Evaluation | Status |
|---|---|---|---|---|
| VCV000037346 | SLCO1B1, 521T>C, Val174Ala | drug response | 2022-02-15 | 1A |
| VCV000017848 | APOE, 526C>T, Arg176Cys | drug response | 2021-03-24 | 2B |
Financial
Lipitor - Viatris
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Lipitor - Pfizer
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Caduet - Pfizer
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 40,489 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
33,308 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more